Boston Scientific Corporation (BSX)
USD 88.03
(-2.65%)
USD 88.03
(-2.65%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 3.45 Billion USD | 29.29% |
| 2022 | 2.74 Billion USD | 0.57% |
| 2021 | 2.51 Billion USD | 51.88% |
| 2020 | 1.51 Billion USD | -11.96% |
| 2019 | 2.21 Billion USD | -13.79% |
| 2018 | 2.58 Billion USD | 22.4% |
| 2017 | 2 Billion USD | 7.99% |
| 2016 | 1.22 Billion USD | 26.35% |
| 2015 | 360 Million USD | 7.27% |
| 2014 | 433 Million USD | 5.73% |
| 2013 | 721 Million USD | -5.42% |
| 2012 | -3.16 Billion USD | -36.77% |
| 2011 | 1.63 Billion USD | 41.85% |
| 2010 | 149 Million USD | 623.69% |
| 2009 | -108 Million USD | 68.63% |
| 2008 | -699 Million USD | -135.76% |
| 2007 | 940 Million USD | -60.75% |
| 2006 | -2.31 Billion USD | 130.52% |
| 2005 | 1.29 Billion USD | 24.86% |
| 2004 | 1.83 Billion USD | 116.95% |
| 2003 | 930 Million USD | 16.52% |
| 2002 | 856 Million USD | 0.34% |
| 2001 | 614 Million USD | -4.39% |
| 2000 | 856 Million USD | -1.89% |
| 1999 | 903 Million USD | 977.42% |
| 1998 | 620 Million USD | -116.86% |
| 1997 | 509 Million USD | 47.3% |
| 1996 | 411.8 Million USD | -15.35% |
| 1995 | 299.9 Million USD | 273.64% |
| 1994 | 139 Million USD | 23.3% |
| 1993 | 115 Million USD | 16.91% |
| 1992 | 97.4 Million USD | 29.99% |
| 1991 | 73.9 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 1 Billion USD | 11.44% |
| 2024 Q3 | 747 Million USD | 29.8% |
| 2024 Q2 | 1.05 Billion USD | -17.48% |
| 2023 Q2 | 798 Million USD | 7.26% |
| 2023 Q4 | 1.01 Billion USD | 26.84% |
| 2023 Q1 | 744 Million USD | -5.22% |
| 2023 Q3 | 801 Million USD | 0.38% |
| 2023 FY | - USD | 29.29% |
| 2022 Q4 | 785 Million USD | 19.12% |
| 2022 FY | - USD | 0.57% |
| 2022 Q3 | 659 Million USD | -7.05% |
| 2022 Q1 | 649 Million USD | -7.15% |
| 2022 Q2 | 709 Million USD | 9.24% |
| 2021 Q2 | 674 Million USD | 14.43% |
| 2021 Q1 | 589 Million USD | -19.65% |
| 2021 Q4 | 699 Million USD | -15.17% |
| 2021 Q3 | 824 Million USD | 22.26% |
| 2021 FY | - USD | 51.88% |
| 2020 FY | - USD | -11.96% |
| 2020 Q1 | 411 Million USD | -31.39% |
| 2020 Q2 | 144 Million USD | -64.96% |
| 2020 Q3 | 544 Million USD | 277.78% |
| 2020 Q4 | 733 Million USD | 34.74% |
| 2019 Q3 | 400 Million USD | -12.66% |
| 2019 FY | - USD | -13.79% |
| 2019 Q4 | 599 Million USD | 49.75% |
| 2019 Q2 | 458 Million USD | -26.48% |
| 2019 Q1 | 623 Million USD | 1.63% |
| 2018 FY | - USD | 22.4% |
| 2018 Q3 | 670 Million USD | 14.33% |
| 2018 Q2 | 586 Million USD | 7.72% |
| 2018 Q1 | 544 Million USD | 2.26% |
| 2018 Q4 | 613 Million USD | -8.51% |
| 2017 Q2 | 473 Million USD | 2.38% |
| 2017 FY | - USD | 7.99% |
| 2017 Q3 | 504 Million USD | 6.55% |
| 2017 Q4 | 532 Million USD | 5.56% |
| 2017 Q1 | 462 Million USD | -2.12% |
| 2016 Q2 | 462 Million USD | 5.0% |
| 2016 Q1 | 440 Million USD | 22.56% |
| 2016 FY | - USD | 26.35% |
| 2016 Q3 | 454 Million USD | -1.73% |
| 2016 Q4 | 472 Million USD | 3.96% |
| 2015 Q1 | 356 Million USD | 6.27% |
| 2015 Q2 | 357 Million USD | 0.28% |
| 2015 Q3 | 372 Million USD | 4.2% |
| 2015 Q4 | 359 Million USD | -3.49% |
| 2015 FY | - USD | 7.27% |
| 2014 FY | - USD | 5.73% |
| 2014 Q4 | 335 Million USD | 6.35% |
| 2014 Q3 | 315 Million USD | -11.02% |
| 2014 Q2 | 354 Million USD | 3.21% |
| 2014 Q1 | 343 Million USD | 11.0% |
| 2013 Q4 | 309 Million USD | -2.22% |
| 2013 Q1 | 308 Million USD | -6.95% |
| 2013 Q2 | 345 Million USD | 12.01% |
| 2013 FY | - USD | -5.42% |
| 2013 Q3 | 316 Million USD | -8.41% |
| 2012 Q2 | 340 Million USD | 8.63% |
| 2012 Q1 | 313 Million USD | 17.23% |
| 2012 FY | - USD | -36.77% |
| 2012 Q4 | 331 Million USD | -10.54% |
| 2012 Q3 | 370 Million USD | 8.82% |
| 2011 FY | - USD | 41.85% |
| 2011 Q1 | 1.19 Billion USD | 86.72% |
| 2011 Q2 | 370 Million USD | -69.04% |
| 2011 Q3 | 308 Million USD | -16.76% |
| 2011 Q4 | 267 Million USD | -13.31% |
| 2010 Q3 | 390 Million USD | 11.11% |
| 2010 Q1 | 365 Million USD | 133.73% |
| 2010 Q2 | 351 Million USD | -3.84% |
| 2010 Q4 | 640 Million USD | 64.1% |
| 2010 FY | - USD | 623.69% |
| 2009 Q1 | 162 Million USD | -78.54% |
| 2009 Q4 | -1.08 Billion USD | -325.42% |
| 2009 Q3 | 480 Million USD | 8.84% |
| 2009 Q2 | 441 Million USD | 172.22% |
| 2009 FY | - USD | 68.63% |
| 2008 Q4 | 755 Million USD | 524.16% |
| 2008 Q3 | -178 Million USD | -128.57% |
| 2008 Q2 | 623 Million USD | 83.24% |
| 2008 Q1 | 340 Million USD | -56.13% |
| 2008 FY | - USD | -135.76% |
| 2007 FY | - USD | -60.75% |
| 2007 Q4 | 775 Million USD | 48.18% |
| 2007 Q3 | 523 Million USD | 21.63% |
| 2007 Q2 | 430 Million USD | 2.63% |
| 2007 Q1 | 419 Million USD | -24.37% |
| 2006 Q4 | 554 Million USD | 36.45% |
| 2006 Q3 | 406 Million USD | -91.34% |
| 2006 Q2 | 4.68 Billion USD | 731.38% |
| 2006 Q1 | 564 Million USD | 2.36% |
| 2006 FY | - USD | 130.52% |
| 2005 Q4 | 551 Million USD | 2.42% |
| 2005 Q3 | 538 Million USD | -34.95% |
| 2005 Q2 | 827 Million USD | 10.27% |
| 2005 FY | - USD | 24.86% |
| 2005 Q1 | 750 Million USD | 20.0% |
| 2004 Q2 | 656 Million USD | 114.38% |
| 2004 Q4 | 625 Million USD | 21.36% |
| 2004 FY | - USD | 116.95% |
| 2004 Q1 | 306 Million USD | 24.39% |
| 2004 Q3 | 515 Million USD | -21.49% |
| 2003 Q4 | 227 Million USD | 4.24% |
| 2003 Q2 | 206 Million USD | 3.13% |
| 2003 Q1 | 188 Million USD | -16.73% |
| 2003 FY | - USD | 16.52% |
| 2003 Q3 | 202 Million USD | 2.16% |
| 2002 FY | - USD | 0.34% |
| 2002 Q4 | 216 Million USD | 52.84% |
| 2002 Q3 | 265 Million USD | -18.14% |
| 2002 Q2 | 144 Million USD | 46.26% |
| 2002 Q1 | 142 Million USD | -77.93% |
| 2001 Q2 | 94 Million USD | 28.82% |
| 2001 Q4 | 417 Million USD | 372.34% |
| 2001 FY | - USD | -4.39% |
| 2001 Q1 | 142 Million USD | -21.58% |
| 2001 Q3 | 132 Million USD | -52.2% |
| 2000 Q3 | 188 Million USD | 0.0% |
| 2000 Q1 | 203 Million USD | -34.39% |
| 2000 Q2 | 215 Million USD | 5.83% |
| 2000 FY | - USD | -1.89% |
| 2000 Q4 | 250 Million USD | 33.94% |
| 1999 Q1 | 222 Million USD | 118.72% |
| 1999 Q4 | 303 Million USD | 112.16% |
| 1999 Q3 | 148 Million USD | -41.73% |
| 1999 Q2 | 238 Million USD | 7.63% |
| 1999 FY | - USD | 977.42% |
| 1998 FY | - USD | -116.86% |
| 1998 Q1 | 109.2 Million USD | 267.68% |
| 1998 Q2 | 103.3 Million USD | -5.4% |
| 1998 Q3 | 130 Million USD | 768.73% |
| 1998 Q4 | -486.4 Million USD | -240.51% |
| 1997 Q4 | 29.7 Million USD | -75.19% |
| 1997 FY | - USD | 47.3% |
| 1997 Q1 | 112.8 Million USD | 243.98% |
| 1997 Q2 | 138.8 Million USD | 185.59% |
| 1997 Q3 | 119.7 Million USD | -59.74% |
| 1996 Q1 | 172.1 Million USD | 44.62% |
| 1996 Q4 | -72.3 Million USD | -169.32% |
| 1996 Q3 | 109.1 Million USD | -39.18% |
| 1996 Q2 | 171.5 Million USD | -0.35% |
| 1996 FY | - USD | -15.35% |
| 1995 Q3 | 78.7 Million USD | 9.66% |
| 1995 Q4 | 57 Million USD | 43.55% |
| 1995 FY | - USD | 273.64% |
| 1995 Q1 | 74.2 Million USD | 438.21% |
| 1995 Q2 | 75.2 Million USD | -61.93% |
| 1994 Q4 | 36.9 Million USD | 17.52% |
| 1994 Q2 | 30.7 Million USD | 3.69% |
| 1994 Q1 | 29.7 Million USD | -11.31% |
| 1994 Q3 | 31.4 Million USD | 1.62% |
| 1994 FY | - USD | 23.3% |
| 1993 Q1 | 25 Million USD | -7.52% |
| 1993 Q2 | 27.6 Million USD | 8.54% |
| 1993 Q3 | 28.4 Million USD | 3.75% |
| 1993 Q4 | 33.9 Million USD | 21.3% |
| 1993 FY | - USD | 16.91% |
| 1992 FY | - USD | 29.99% |
| 1992 Q4 | 26.7 Million USD | 8.57% |
| 1992 Q3 | 25.6 Million USD | 6.52% |
| 1992 Q2 | 23.2 Million USD | 5.5% |
| 1992 Q1 | 22 Million USD | 122.78% |
| 1991 Q1 | 50.5 Million USD | 0.0% |
| 1991 Q4 | -95.7 Million USD | -259.77% |
| 1991 Q3 | 59.9 Million USD | 7.16% |
| 1991 FY | - USD | 0.0% |
| 1991 Q2 | 55.9 Million USD | 10.69% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Abbott Laboratories | 10.46 Billion USD | 66.998% |
| Allurion Technologies Inc. | -69.03 Million USD | 5102.101% |
| Artivion, Inc. | 38.14 Million USD | -8953.012% |
| Avanos Medical, Inc. | 53.2 Million USD | -6390.602% |
| Butterfly Network, Inc. | -124.84 Million USD | 2865.852% |
| Butterfly Network, Inc. | -124.84 Million USD | 2865.852% |
| Bio-Rad Laboratories, Inc. | -608.26 Million USD | 667.68% |
| Perspective Therapeutics, Inc. | -14.83 Million USD | 23371.33% |
| CONMED Corporation | 182.18 Million USD | -1795.316% |
| Edwards Lifesciences Corporation | 1.76 Billion USD | -95.35% |
| Paragon 28, Inc. | -36.61 Million USD | 9530.819% |
| Glaukos Corporation | -82.11 Million USD | 4305.027% |
| Globus Medical, Inc. | 418.23 Million USD | -725.604% |
| Inspire Medical Systems, Inc. | -17.06 Million USD | 20340.328% |
| Integer Holdings Corporation | 282.05 Million USD | -1124.212% |
| Medtronic plc | 9.05 Billion USD | 61.871% |
| Nevro Corp. | -78.31 Million USD | 4509.399% |
| Owlet, Inc. | -27.48 Million USD | 12661.388% |
| Penumbra, Inc. | 111.99 Million USD | -2983.146% |
| Vicarious Surgical Inc. | -69.19 Million USD | 5090.461% |
| Smith & Nephew plc | 979 Million USD | -252.707% |
| Sonendo, Inc. | -54.76 Million USD | 6404.777% |
| STERIS plc | 1.41 Billion USD | -144.477% |
| Stryker Corporation | 5.16 Billion USD | 33.081% |
| Vapotherm, Inc. | -34.35 Million USD | 10150.354% |
| Zimmer Biomet Holdings, Inc. | 2.44 Billion USD | -41.002% |